NEXYZ.Group (4346) · FactDropped
Sluggish sales of DNA test-based health consulting
First written in FY2016. 1 of 3 entries say "Restated". Latest entry: FY2018.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Profit decline due to low utilization of the individual genetic analysis serviceA theme 2 companies write about · 2 as a headwind · 0 as a tailwind
0 other companies' latest entry also says "Dropped".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2018DroppedAnnual report
「Because the significance of the consolidated subsidiaries Nexyz Trade Co., Ltd. and DiNA had declined, they were excluded from the scope of consolidation. Accordingly, the Other segment is no longer presented.」
The Other segment is no longer presented, and the weak sales of DNA testing-based health consulting previously reported are not carried forward as an ongoing theme in this filing. - FY2017RestatedAnnual report
「Meanwhile, sales of analysis kits and supplements were weak in the DNA testing-based health consulting business.」
The company again reported weak sales of DNA testing- and supplement-related products for the full fiscal year. - FY2016First statedAnnual report
「Meanwhile, sales of analysis kits and supplements were weak in the DNA testing-based health consulting business.」
The company reports that sales were weak for DNA testing- and supplement-related products in the Life Amenity business.